Table 2.

Data collection measures

Outcome	Test	Measurement
Primary outcome measures	Glycosylated haemoglobin A1c	Blood specimen will be obtained at screening, 3, 6, 9, 12, and 18 months
	Utilisation and cost	Previously validated questions on resource utilisation will be administered. The questionnaires capture information on hospitalisations, physician/professional visits and medications
Secondary outcome measures	Blood pressure	Blood pressure will be obtained at screening, 3, 6, 9, 12, and 18 months. Blood pressure readings will be obtained using automated BP monitors (OMRON IntelliSense HEM-907XL). The device will be programmed to take 3 readings at 2 min intervals and give an average of the 3 BP readings
	LDL cholesterol	Low-density lipoprotein (LDL) cholesterol will be obtained at the screening, 3, 6, 9, 12, and 18 months. About 10 cc of blood will be drawn by trained phlebotomists and sent to the laboratory for LDL cholesterol
	Quality of life	The 12-item Short Form Survey (SF-12) is a valid and reliable instrument to measure functional status and reproduces 90% of the variance in PCS-36 and MCS-36 scores27
	Behavioural skills	Behavioural skills will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA), a brief, validated questionnaire of diabetes self-care28
	Medication adherence	Medication adherence will be measured with the 6-item validated self-report Brooks Medication Adherence Scale (BMAS).29 Each of 6 items measures a specific medication-taking behaviour29
	Delay discounting	Delay discounting will be measured using the 10-item self-report Quick Delay Questionnaire (QDQ) developed to test two factors: (1) delay discounting and (2) delay aversion. Test–retest for the two factors are r=0.80 for delay discounting and r=0.81 for delay aversion. Internal consistency is satisfactory for both factors (delay discounting—α=0.68; delay aversion—α=0.77)30
Covariates	Patient demographics	Demographics will be measured using validated items from the Behavioral Risk Factor Surveillance System31
	Social support	The Medical Outcomes Study (MOS) Social Support Survey will be used to measure social support32
	Depression	The PHQ-9 will be used to measure depression. The PHQ-9 is a brief questionnaire that scores each of the 9 DSM-IV criteria for depression as “0” (not at all) to “3” (nearly every day). PHQ-9 score ≥10 have a sensitivity of 88% and a specificity of 88% for major depression33
	Medical comorbidity	Medical comorbidity will be assessed using previously validated questions regarding chronic disease from the Behavioral Risk Factor Surveillance System31
	Health literacy	This will be assessed by the three-item CHEW34